Background: The majority of seasonal affective disorder (SAD) studies have evaluated the use of light or selective serotonin reuptake inhibitors (SSRI). The purpose of the present study was to evaluate bupropion sustained-released (SR), a non-SSRI antidepressant, for the treatment of SAD.

Objective: The Improving Access to Psychological Therapies (IAPT) initiative was introduced in the UK to increase access to psychological therapies for those with mild to moderate anxiety and depression. Recent outcome figures suggest recovery rates of 42%. One potential reason for non-recovery is the experience of previous trauma and potential PTSD comorbidity, which has been found to negatively impact treatment for anxiety and depression. This study therefore aimed to investigate trauma levels in IAPT patients.

Purpose: The aim of the study was to investigate the possible impact of Binge Eating Disorder (BED) on quality of life (QoL), social anxiety, and perceived mental health in obese patients suffering from psychosis and mood disorder.

The treatment of bipolar depression is the subject of intensive research, as shown by the numerous references obtained only in the last year using the terms “bipolar depression and treatment” in MEDLINE. This is one of the signs of effervescence in the treatment of this affection leading to publication of consensus in North America and the United Kingdom which often don’t deal with clinical realities [1].

The trait of amotivation is commonly clinically described among chronic cannabis abusers but few empirical studies have provided data on this dimension. Thus, our objective was to determine to what extent apathy, evaluated in a multidimensional approach, is associated with cannabis use and misuse in a community sample of young adults. 677 participants with a mean age of 20.5 years completed several web-formatted self-reports including the Lille Apathy Rating Scale (LARS) adapted to a self-report format (LARS-SR) and the 13-item Beck Depression Inventory (BDI-13). Participants were asked about their use of cannabis and, if appropriate, the Cannabis Abuse Screening Test (CAST) was completed. The problematic CU according to the CAST presented higher scores on the LARS-SR total score, LARS-SR subscales “intellectual curiosity”, “emotion”, and “action initiation” and he BDI-13 in comparison with non-problematic users. Regression analyses revealed that both apathy and depression were significant predictors of the CAST categories (non-symptomatic vs. moderate/severe). Despite some limitations, our study about the impairment of motivational functioning provides some new insight into the clinical implications of problematic patterns of cannabis use. Indeed, apathy was associated with both cannabis use and more severe patterns of cannabis use as evaluated with the CAST. The use of a scale investigating apathy as a multidimensional construct reveals that only some apathy dimensions seem involved in cannabis misuse independently of depression.